Lecanemab – other CNS disorders

The drug candidate lecanemab, which is currently being clinically evaluated for Alzheimer’s disease, can potentially also be used for other indications which are owned by BioArctic. The antibody lecanemab is in the pre-clinical phase as a potential treatment of cognitive disorders in conjunction with Down’s syndrome and traumatic brain injuries.